Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|AMG 900||AMG900|AMG-900||AURK Inhibitor (Pan) 11||AMG 900 selectively binds to and inhibits the activities of Aurora kinases A, B and C, which may result in inhibition of cellular division and proliferation in tumor cells that overexpress these kinases (PMID: 25367255, PMID: 32138169).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||triple-receptor negative breast cancer||not applicable||AMG 900||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AMG 900 induced apoptosis in triple-negative breast cancer (TNBC) cell lines in culture and inhibited tumor growth in TNBC cell line xenograft models (PMID: 23990115).||23990115|
|Unknown unknown||Advanced Solid Tumor||not applicable||AMG 900||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AMG 900 inhibited the growth of a variety of human solid tumor cell lines in culture and inhibited tumor growth in cell line xenograft models of several tumor types including breast, colon, lung, pancreatic, and uterine cancer (PMID: 20935223).||20935223|
|Unknown unknown||colon cancer||not applicable||AMG 900||Preclinical - Cell line xenograft||Actionable||In a preclinical study, AMG 900 inhibited growth of colon cancer cell lines in culture, and inhibited tumor growth in colon cancer cell line xenograft models (PMID: 20935223).||20935223|
|Unknown unknown||acute myeloid leukemia||not applicable||AMG 900||Phase I||Actionable||In a Phase I clinical trial, AMG 900 treatment resulted in a complete response in 9% (3/35) of adult patients acute myeloid leukemia (PMID: 28370201).||28370201|
|TP53 inact mut||breast cancer||sensitive||AMG 900||Preclinical||Actionable||In a preclinical study, breast cancer cell lines with TP53 loss of function mutations had more pronounced apoptosis after treatment with AMG 900 in culture (PMID: 24091768).||24091768|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT00858377||Phase I||AMG 900||A Phase 1 First-in-Human Study Evaluating AMG 900 in Advanced Solid Tumors||Completed||USA||1|